Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PCTP | Q9UKL6 | 1/20 | 0.44 |
| ▸ | STARD10 | Q9Y365 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715747 | 0.89 | MAPT (0.52) | MAPTTDP1MEN1KMT2AGFER | |
| SCHEMBL6720022 | 0.85 | MEN1 (0.63) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6727005 | 0.85 | MAPT (0.50) | MAPTTDP1MEN1KMT2AGFER | |
| SCHEMBL6717397 | 0.84 | LMNA (0.53) | MAPTTDP1MEN1KMT2AGAA | |
| SCHEMBL6719554 | 0.84 | NPY5R (0.50) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL6726997 | 0.84 | MAPT (0.50) | MAPTTDP1MEN1KMT2AGAA | |
| SCHEMBL6718590 | 0.84 | KMT2A (0.50) | MAPTTDP1MEN1KMT2AGAA | |
| SCHEMBL6713932 | 0.81 | KDM4E (0.46) | MAPTTDP1MEN1KMT2AGAA | |
| SCHEMBL6718048 | 0.81 | KLK7 (0.46) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL6714045 | 0.81 | MAPT (0.61) | MAPTMEN1KMT2AGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | MAPT 694/4885TDP1 1239/4885MEN1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.